ADAR1 Capital Management, the largest stockholder of Keros Therapeutics with approximately 13.3% of the company's outstanding shares, has released an investor presentation recommending that votes be withheld for the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the Keros Board of Directors. This recommendation comes ahead of Keros Therapeutics' Annual Meeting of Stockholders, scheduled for June 4, 2025. ADAR1's decision and the rationale behind it can be found in their presentation, which has been made publicly accessible.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.